ISSN 2756-3855
International Journal of Urology and Nephrology ISSN 2091-1254 Vol. 7 (7), pp. 001-006, July, 2019. © International Scholars Journals
Full Length Research Paper
The antitumor effects of Araloside A extracted from the root bark of Aralia elata on human kidney cancer cell lines
Liu Yu1, Liu Jinfeng2, Liu Zhenhong3, Liu Yanju3, Liu Mingna2, Jiang Jing2 and Xu Wanhai1*
1The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, PR China.
2The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, PR China.
3Harbin Medical University, Harbin, Heilongjiang 150001, P. R. China.
Accepted 12 April, 2019
Abstract
Aralia elata was used as therapeutic medicine in oriental courtiers a few hundred years ago. As one important constituent extracted from Aralia elata, Araloside A has been shown to treat gastric ulcers, hepatitis, and arrhythmias. It is not yet known, however, whether Araloside A may induce cell apoptosis in renal cell carcinoma. We therefore examined the antitumor effects of Araloside A on human kidney cancer cell lines GRC- 1 and 786-O. We found that Araloside A 1, 3, 10, 30 and 100 M caused a considerable reduction of cellular viability of GRC-1 1 and 786-O cells in a dose- and time-dependent manner. The number of Tunnel-positive cancer cells was also higher in cells treated with Araloside A than untreated cells. The real-time polymerase chain reaction (PCR) techniques showed that Araloside A was able to increase the expression of bax mRNA and inhibited the expression of bcl-2 mRNA. Conclusively, Araloside A has a remarkably antitumor effect on kidney tumor cells through regulating bax/bcl-2 ratio.
Key words: Araloside A, antitumor, bax/bcl-2.